Registering patients undergoing heated chemotherapy for peritoneal cancers
Official title: Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed
Run by Universitaire Ziekenhuizen KU Leuven · NCT01617382 · Data updated 2026-11-12
This study is collecting information from patients with certain abdominal cancers who are having surgery followed by heated chemotherapy to see if it helps them live longer and feel better.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 125 (estimated) |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Leuven, Flemish Brabant) |
| Status | Recruiting |
| Started | May 2012 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT01617382 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with peritoneal carcinomatosis of colorectal origin, pseudomyxoma peritonei, or peritoneal mesothelioma who are scheduled for cytoreductive surgery and HIPEC.
✕Probably not a fit
Patients with peritoneal malignancies not eligible for cytoreductive surgery or HIPEC may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect follow-up data from patients diagnosed with peritoneal surface malignancies who will undergo cytoreductive surgery followed by hyperthermic intra-peritoneal chemotherapy (HIPEC). The procedure involves removing visible tumors from the abdominal cavity and rinsing it with heated chemotherapy to eliminate any remaining cancer cells. The goal is to improve patient survival and prognosis by ensuring thorough treatment of peritoneal carcinomatosis, pseudomyxoma peritonei, and peritoneal mesothelioma.
Why it matters
Potential benefit: If successful, this approach could significantly enhance survival rates for patients with peritoneal surface malignancies.
How similar studies have gone: Other studies have shown promising results with HIPEC in similar patient populations, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
Where it's running
-
University Clinics Gasthuisberg
Leuven, Flemish Brabant, Belgium Recruiting
Study contacts
- Principal investigator: André JL D'Hoore, PhD — University Clinics Gasthuisberg Department of Abdominal Surgery
- Study coordinator: Isabelle B Terrasson
- Email: isabelle.terrasson@uzleuven.be
- Phone: +32 16 340837
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized chemotherapy for abdominal cancer treatment
This study is testing a new way to personalize chemotherapy for patients with abdominal cancer by trying different treatments on their tumor samples before using them during surgery.
-
Using cardiac coherence to reduce anxiety in patients with peritoneal carcinosis before surgery
This study is testing if teaching patients with peritoneal carcinosis some breathing techniques can help reduce their anxiety before surgery.
-
Appendix Cancer and PMP Patient Registry and Natural History Study
This global, patient-powered registry tests how appendix cancer and pseudomyxoma peritonei progress over time by collecting real-world data from patients and caregivers.
-
Metformin in PMP from appendiceal mucinous neoplasms
This pilot study tests whether metformin is feasible to use in adults with pseudomyxoma peritonei caused by appendiceal mucinous tumors who have recurrent or unresected disease.
-
Repeated PIPAC plus standard platinum–taxane chemotherapy for advanced ovarian cancer with peritoneal spread
This test sees if adding repeated cisplatin-based PIPAC to standard platinum–taxane chemotherapy helps women aged 18–75 with newly diagnosed FIGO IIIB–IIIC epithelial ovarian cancer and visible peritoneal carcinomatosis.
-
Enhanced Recovery After Surgery for adults with peritoneal carcinomatosis undergoing cytoreductive surgery with or without HIPEC
This project will try an Enhanced Recovery After Surgery (ERAS) program to see if it shortens hospital stays after cytoreductive surgery with or without HIPEC for adults with peritoneal carcinomatosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.